© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Jonathon B. Cohen, MD, MS
Articles
The Role of the Comprehensive Geriatric Assessment in the Evaluation of the Older Cancer Patient
November 14, 2019
ByCarmelo Blanquicett, MD, PhD, FACP|Theodore Johnson, II, MD, MPH|Christopher Flowers, MD, MS|Jonathon B. Cohen, MD, MSGeriatric assessments have now been recommended as part of the standard evaluation of an older adult considering cancer therapy.
How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis
June 15, 2018
ByKevin H. Hall, PharmD, BCOP|Elyse Hall Panjic, PharmD, BCOP|Kelly Valla, PharmD, BCOP|Christopher R. Flowers, MD, MS|Jonathon B. Cohen, MD, MSHere we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
PI3K Inhibitors: Understanding Toxicity Mechanisms and Management
November 15, 2017
ByI. Brian Greenwell, MD|Andrew Ip, MD|Jonathon B. Cohen, MD, MSHere, we briefly describe the clinical efficacy of PI3K inhibitors, then discuss the mechanisms and management of the more common unusual toxicities seen with these agents.
A Plethora of Novel Therapies-Which One to Choose?
July 15, 2015
ByJonathon B. Cohen, MD, MS|Christopher R. Flowers, MD, MSWhile the headliners for the 2015 ASCO Annual Meeting featured mainly immunologic approaches to cancer treatment, with agents such as nivolumab and ipilimumab, the new data in hematologic malignancies highlighted a large number of novel therapies, each of which appears promising.